BioNTech and Pfizer: The next COVID-19 vaccine deal

BioNTech and Pfizer have agreed a supply contract with another government for the COVID-19 vaccine under development. Just started the clinical test phase 2b / 3 for the project under the name BNT162. The Mainz-based biotech company and its US partner group want to have the vaccine approved in their pocket by 2020 and produce up to 100 million doses. In the coming year it will be 1.3 billion cans.

Part of the production that is planned is to be delivered to Japan from 2021 – provided that the vaccine is actually approved for the market. The government has agreed to supply 120 million BNT162 vaccine doses against the SARS-CoV-2 virus that triggered the pandemic. Deliveries are expected to take place in the first half of the year. Neither BioNtech nor Pfizer provide more specific information about the financial details of the order.

The two companies had previously announced vaccine deals with governments. The US government has placed an initial order for 100 million cans for $ 1.95 billion, it said last week. The U.S. government also has an option to deliver an additional 500 million doses of the SARS-CoV-2 virus vaccine. 30 million doses of vaccine have been ordered from the UK.


Related Articles

Back to top button